Cited by 204Lipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismPharmacogenetics and Drug Metabolism

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects

Cilla, Donald D., Whitfield, Lloyd R., Gibson, Donald M., Sedman, Allen J., Posvar, Edward L.·1996·Clinical Pharmacology & Therapeutics

DOI 10.1016/s0009-9236(96)90218-0

Open this paper in CoChat — free account

Abstract

This study examined the pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an investigational inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, in 50 healthy subjects by means of a randomized, double-blind parallel-group design. Volunteers received rising single and multiple doses of 0.5 to 80 mg/day atorvastatin (40 subjects) or placebo (10 subjects). The drug was administered once or twice daily for 14 days. Atorvastatin was well tolerated by healthy subjects. The most common adverse events reported after atorvastatin-headache and nausea-occurred as frequently after placebo. Atorvastatin peak concentration and area under the plasma concentration-time curve (AUC) values increased more than proportionally with atorvastatin dose after both single and multiple drug doses. The extent of atorvastatin absorption (AUC) was similar after once- or twice-daily drug administration. Steady-state drug concentrations were achieved by the third day of drug dosing. Mean elimination half-life values ranged from 11 to 24 hours. Atorvastatin accumulation was approximately 1.5- and 3.0-fold after once- and twice-daily administration, respectively. Atorvastatin produced dose-related reductions in total cholesterol and low-density lipoprotein cholesterol that were similar after once- and twice-daily drug administration. Reductions in mean total cholesterol and low-density lipoprotein cholesterol values ranged from 13% and 22% (2.5 mg/day) to 45% and 58% (80 mg/day), respectively (p < or = 0.0013 in comparison with placebo and with baseline over this dose range). In summary, atorvastatin doses of up to 80 mg/day were well tolerated and had significant cholesterol-lowering effects.

Integrity signals

Registry

Crossref · 10.1016/s0009-9236(96)90218-0

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase Inhibitor
Nawrocki, J. W., Weiss, S. R., Davidson, M. H., Sprecher, D. L., Schwartz, S. L., Lupien, P.-J., Jones, P. H., Haber, H. E., & Black, D. M. (1995) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.15.5.678 · Cited by 484
Efficacy and Safety of a New HMG-CoA Reductase Inhibitor, Atorvastatin, in Patients With Hypertriglyceridemia
Bakker-Arkema, R. G. (1996) · JAMA · doi:10.1001/jama.1996.03530260042029 · Cited by 406
Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers.
Tobert, J. A., Bell, G. D., Birtwell, J., James, I. M., Kukovetz, W. R., Pryor, J., Buntinx, A., Holmes, I. B., Chao, Y. S., & Bolognese, J. A. (1982) · Journal of Clinical Investigation · doi:10.1172/jci110530 · Cited by 204
Comparative Pharmacokinetics and Pharmacodynamics of Pravastatin and Lovastatin
Pan, H., DeVault, A. R., Wang‐Iverson, D. B., Ivashkiv, E., Swanson, B. N., & Sugerman, A. A. (1990) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1990.tb01856.x · Cited by 146
Tolerance and Pharmacokinetics of Single‐Dose Atorvastatin, a Potent Inhibitor of HMG‐CoA Reductase, in Healthy Subjects
Posvar, E. L., Radulovic, L. L., Cilla, D. D., Whitfield, L. R., & Sedman, A. J. (1996) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1996.tb04242.x · Cited by 91
Self-citation
Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia.
Leitersdorf, E., Eisenberg, S., Eliav, O., Friedlander, Y., Berkman, N., Dann, E., Landsberger, D., Sehayek, E., Meiner, V., & Wurm, M. (1993) · PubMed · Cited by 86
A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin.
Levy, R. I., Aj, T., & Jm, F. (1993) · PubMed · Cited by 69
HMG-CoA reductase inhibitors: a look back and a look ahead.
Davignon, J., Montigny, M., & Dufour, R. (1992) · PubMed · Cited by 63

Show all 8 references

Research works printed but not linked: 6

Shaw M. K., 1990, FASEB J, 4, A533
Krause B. R., 1993, FASEB J, 7, A567
Shum Y. Y., 1993, Pharm Res, 10, S-415
Levy R. I., 1993, Circulation, 87, 45
Davignon J., 1992, Can J Cardiol, 8, 843
Leitersdorf E., 1993, Circulation, 87, 35

Sorted by citations

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease
Youssef, S., Stüve, O., Patarroyo, J. C., Ruiz, P. J., Radosevich, J. L., Hur, E. M., Bravo, M., Mitchell, D. J., Sobel, R. A., Steinman, L., et al. (2002) · Nature · doi:10.1038/nature01158 · Cited by 1,096
New insights into the pharmacodynamic and pharmacokinetic properties of statins
Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R., & Bernini, F. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00045-5 · Cited by 796
Statins Have Biphasic Effects on Angiogenesis
Weis, M., Heeschen, C., Glassford, A. J., & Cooke, J. P. (2002) · Circulation · doi:10.1161/hc0602.103393 · Cited by 677
Clinical Pharmacokinetics of Atorvastatin
s, H. L. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342130-00005 · Cited by 636
Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase Inhibitors: Similarities and Differences
Lennernäs, H., & Fager, G. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732050-00005 · Cited by 527
HMG-CoA Reductase Inhibitors Improve Endothelial Dysfunction in Normocholesterolemic Hypertension via Reduced Production of Reactive Oxygen Species
Waßmann, S., Laufs, U., Bäumer, A. T., Müller, K., Ahlbory, K., Linz, W., Itter, G., Rösen, R., Böhm, M., & Nickenig, G. (2001) · Hypertension · doi:10.1161/01.hyp.37.6.1450 · Cited by 453
Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation
Aviram, M., Rosenblat, M., Bisgaier, C. L., & Newton, R. S. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(98)00032-x · Cited by 291
Atorvastatin
Lea, A. P., & McTavish, D. (1997) · Drugs · doi:10.2165/00003495-199753050-00011 · Cited by 292
Safety and Efficacy of Atorvastatin for Chronic Subdural Hematoma in Chinese Patients
Jiang, R., Zhao, S., Wang, R., Feng, H., Zhang, J., Li, X., Mao, Y., 袁贤瑞, Fei, Z., Zhao, Y., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.2030 · Cited by 284
Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process
Kim, M., Jin, S.-J., Kim, J.-S., Park, H. J., Song, H.-S., Neubert, R. H. H., & Hwang, S. (2008) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.01.007 · Cited by 267
Heme Oxygenase-1 and the Vascular Bed: From Molecular Mechanisms to Therapeutic Opportunities
Łoboda, A., Jaźwa, A., Grochot‐Przeczek, A., Rutkowski, A. J., Cisowski, J., Agarwal, A., Józkowicz, A., & Dulak, J. (2008) · Antioxidants and Redox Signaling · doi:10.1089/ars.2008.2043 · Cited by 265
Anti-Angiogenic and Anti-Inflammatory Effects of Statins: Relevance to Anti-Cancer Therapy
Dulak, J., & Józkowicz, A. (2005) · Current Cancer Drug Targets · doi:10.2174/156800905774932824 · Cited by 235
Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs
Ieiri, I., Higuchi, S., & Sugiyama, Y. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902976854 · Cited by 211
Preparation and evaluation of self-microemulsifying drug delivery systems (SMEDDS) containing atorvastatin
Shen, H.-R., & Zhong, M. (2006) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.58.9.0004 · Cited by 199
Atorvastatin Transport in the Caco-2 Cell Model: Contributions of P-Glycoprotein and the Proton-Monocarboxylic Acid Co-Transporter
Wu, X., Whitfield, L. R., & Stewart, B. H. (2000) · Pharmaceutical Research · doi:10.1023/a:1007525616017 · Cited by 189
Self-citation
Statin drug interactions and related adverse reactions: an update
Bellosta, S., & Corsini, A. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1394455 · Cited by 179
Increased Expression of Interleukin-1 in Coronary Artery Disease With Downregulatory Effects of HMG-CoA Reductase Inhibitors
Wæhre, T., Yndestad, A., Smith, C., Haug, T., Tunheim, S. H., Gullestad, L. L., Frøland, S. S., Semb, A. G., Aukrust, P., & Damås, J. K. (2004) · Circulation · doi:10.1161/01.cir.0000125700.33637.b1 · Cited by 163
Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells.
Collisson, E. A., Kleer, C. G., Wu, M., De, A., Gambhir, S. S., Merajver, S. D., & Kolodney, M. S. (2003) · PubMed · Cited by 151
Pharmacokinetic Interactions between Nelfinavir and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Atorvastatin and Simvastatin
Hsyu, P., Schultz-Smith, M. D., Lillibridge, J. H., Lewis, R. H., & Kerr, B. M. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3445-3450.2001 · Cited by 143
Fingerprinting of Helicobacter pylori strains by matrix-assisted laser desorption/ionization mass spectrometric analysis
Nilsson, C. L. (1999) · Rapid Communications in Mass Spectrometry · doi:10.1002/(sici)1097-0231(19990615)13:11 · Cited by 73
Long-term statins administration exacerbates diabetic nephropathy via ectopic fat deposition in diabetic mice
Huang, T., Wu, T., Wu, Y., Li, X., Tan, J. H., Shen, C., Xiong, S., Feng, Z.-Q., Gao, S., Li, H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-35944-z · Cited by 134
Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients.
Lins, R. L., Matthys, K. E., Verpooten, G. A., Peeters, P. C., Dratwa, M., Stolear, J.-C., & Lameire, N. H. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg048 · Cited by 128
Influence of Drug Transporter Polymorphisms on Pravastatin Pharmacokinetics in Humans
Kivistö, K. T., & Niemi, M. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9159-2 · Cited by 130
Statins and their role in vascular protection
Mason, J. C. (2003) · Clinical Science · doi:10.1042/cs20030148 · Cited by 117
Salmonella enterica Serovar Typhimurium Requires Nonsterol Precursors of the Cholesterol Biosynthetic Pathway for Intracellular Proliferation
Catron, D. M., Lange, Y., Borensztajn, J., Sylvester, M. D., Jones, B. D., & Haldar, K. (2004) · Infection and Immunity · doi:10.1128/iai.72.2.1036-1042.2004 · Cited by 111
Enhanced bioavailability of nano-sized chitosan–atorvastatin conjugate after oral administration to rats
Anwar, M., Warsi, M. H., Mallick, N., Akhter, S., Gahoi, S., Jain, G. K., Talegaonkar, S., Ahmad, F. J., & Khar, R. K. (2011) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2011.08.001 · Cited by 110
Induction of the Cytoprotective Enzyme Heme Oxygenase-1 by Statins Is Enhanced in Vascular Endothelium Exposed to Laminar Shear Stress and Impaired by Disturbed Flow
Ali, F., Zakkar, M., Karu, K., Lidington, E. A., Hamdulay, S., Boyle, J. J., Zloh, M., Bauer, A., Haskard, D. O., Evans, P. C., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.009886 · Cited by 104
Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity
Zeiser, R., Youssef, S., Baker, J. B., Kambham, N., Steinman, L., & Negrin, R. S. (2007) · Blood · doi:10.1182/blood-2007-08-106005 · Cited by 99
Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review
Calvarysky, B., Dotan, I., Shepshelovich, D., Leader, A., & Cohen, T. D. (2024) · Drug Safety · doi:10.1007/s40264-023-01392-3 · Cited by 97
Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: A novel mechanism of action
Barone, E., Cenini, G., Domenico, F. D., Martin, S. K., Rukhsana Sultana, A., Mancuso, C., Murphy, M. P., Head, E., & Butterfield, D. A. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.12.007 · Cited by 93
Statin-Induced Expression of Decay-Accelerating Factor Protects Vascular Endothelium Against Complement-Mediated Injury
Mason, J. C., Ahmed, Z., Mankoff, R., Lidington, E. A., Ahmad, S. R., Bhatia, V. K., Kinderlerer, A. R., RANDI, A. M., & Haskard, D. O. (2002) · Circulation Research · doi:10.1161/01.res.0000038151.57577.19 · Cited by 91
Statin drug interactions and related adverse reactions
Bellosta, S., & Corsini, A. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.712959 · Cited by 111
High-dose atorvastatin causes regression of endometriotic implants: a rat model
Öktem, M., Esinler, İ., Eroğlu, D., Haberal, N., Bayraktar, N., & Zeyneloğlu, H. B. (2007) · Human Reproduction · doi:10.1093/humrep/del505 · Cited by 85
Development of a solidified self-microemulsifying drug delivery system (S-SMEDDS) for atorvastatin calcium with improved dissolution and bioavailability
Yeom, D. W., Son, H. Y., Kim, J. H., Kim, S. R., Lee, S. G., Song, S. H., Chae, B. R., & Choi, Y. W. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.04.059 · Cited by 82
Pharmacodynamics and Pharmacokinetic-Pharmacodynamic Relationships of Atorvastatin, an HMG-CoA Reductase Inhibitor
Stern, R. H., Yang, B., Hounslow, N. J., MacMahon, M., Abel, R. B., & Olson, S. C. (2000) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.2000.tb05987.x · Cited by 82
Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage
Harangi, M., Seres, I., Varga, Z., Emri, G., Szilv�ssy, Z., Paragh, G., & Remenyik, �. (2004) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-004-0820-6 · Cited by 81
Atorvastatin causes depressor and sympatho-inhibitory effects with upregulation of nitric oxide synthases in stroke-prone spontaneously hypertensive rats
Kishi, T., Hirooka, Y., Mukai, Y., Shimokawa, H., & Takeshita, A. (2003) · Journal of Hypertension · doi:10.1097/00004872-200302000-00030 · Cited by 81
Atorvastatin Improves the Course of Ischemic Acute Renal Failure in Aging Rats
Sabbatini, M., Pisani, A., Uccello, F., Serio, V., Serù, R., Paternò, R., Cianciaruso, B., Fuíano, G., & Andreucci, M. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000119573.01290.ae · Cited by 79
Biliverdin reductase‐A: a novel drug target for atorvastatin in a dog pre‐clinical model of Alzheimer disease
Barone, E., Mancuso, C., Di Domenico, F., Sultana, R., Murphy, M. P., Head, E., & Butterfield, D. A. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07538.x · Cited by 75
Atorvastatin and Celecoxib in Combination Inhibits the Progression of Androgen-Dependent LNCaP Xenograft Prostate Tumors to Androgen Independence
Zheng, X., Cui, X., Gao, Z., Zhao, Y., Lin, Y., Shih, W. J., Huang, M., Liu, Y., Rabson, A. B., Reddy, B. S., et al. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-09-0059 · Cited by 75
Chitosan based atorvastatin nanocrystals: effect of cationic charge on particle size, formulation stability, and in-vivo efficacy
Kurakula, M., Sobahi, T. R., Abdelaal, M. Y., & El-Helw, A.-R. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s77731 · Cited by 71
Effectiveness of Ezetimibe Alone or in Combination With Twice a Week Atorvastatin (10 mg) for Statin Intolerant High-Risk Patients
Athyros, V. G., Τζιόμαλος, Κ., Kakafika, A. I., Koumaras, H., Karagiannis, A. I., & Mikhailidis, D. P. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.09.096 · Cited by 71
Renal Dysfunction Does Not Alter the Pharmacokinetics or LDL‐Cholesterol Reduction of Atorvastatin
Stern, R. H., Yang, B. ‐., Horton, M. W., Moore, S., Abel, R. B., & Olson, S. C. (1997) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1997.tb05629.x · Cited by 69
Synergistic Inhibition of Lung Tumorigenesis by a Combination of Green Tea Polyphenols and Atorvastatin
Lü, G., Xiao, H., You, H., Lin, Y., Jin, H., Snagaski, B., & Yang, C. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1860 · Cited by 67
Atorvastatin treatment in a dog preclinical model of Alzheimer's disease leads to up-regulation of haem oxygenase-1 and is associated with reduced oxidative stress in brain
Butterfield, D. A., Barone, E., Domenico, F. D., Cenini, G., Rukhsana Sultana, A., Murphy, M. P., Mancuso, C., & Head, E. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001118 · Cited by 69
The expression of efflux and uptake transporters are regulated by statins in Caco-2 and HepG2 cells
Rodrigues, A. C., Curi, R., Genvigir, F. D. V., Hirata, M. H., & Hirata, R. D. C. (2009) · Acta Pharmacologica Sinica · doi:10.1038/aps.2009.85 · Cited by 69
Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs
Suzuki, H., Aoki, T., Tamaki, T., Sato, F., Kitahara, M., & Saitō, Y. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(99)00146-x · Cited by 65
Dose Discrepancies Between the Physicians' Desk Reference and the Medical Literature, and Their Possible Role in the High Incidence of Dose-Related Adverse Drug Events
Cohen, J. S. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.7.957 · Cited by 64
A Novel Role of Extracellular Nucleotides in Valve Calcification
Osman, L., Chester, A. H., Amrani, M., Yacoub, M. H., & Smolenski, R. T. (2006) · Circulation · doi:10.1161/circulationaha.105.001214 · Cited by 64
Human Platelets Express Organic Anion-Transporting Peptide 2B1, an Uptake Transporter for Atorvastatin
Nießen, J., Jedlitschky, G., Grube, M., Bien, S., Schwertz, H., Ohtsuki, S., Kawakami, H., Kamiie, J., Oswald, S., Starke, K., et al. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.024570 · Cited by 63
Biphasic Effect of HMG-CoA Reductase Inhibitor, Pitavastatin, on Vascular Endothelial Cells and Angiogenesis
Katsumoto, M., Shingu, T., Kuwashima, R., Nakata, A., Nomura, S., & Chayama, K. (2005) · Circulation Journal · doi:10.1253/circj.69.1547 · Cited by 63
Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects
Hausner, H., Derving Karsbøl, J., Holst, A. G., Jacobsen, J. B., Wagner, F.-D., Golor, G., & Anderson, T. W. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0532-6 · Cited by 62
Atorvastatin desensitizes β‐adrenergic signaling in cardiac myocytes via reduced isoprenylation of G‐protein γ‐subunits
Mühlhäuser, U., Zolk, O., Rau, T., Münzel, F., Wieland, T., & Thomas Eschenhagen, A. (2006) · The FASEB Journal · doi:10.1096/fj.05-5067fje · Cited by 60
Efficacy of Alternate-Day Dosing Versus Daily Dosing of Atorvastatin
Jafari, M., Ebrahimi, R., Ahmadi-Kashani, M., Balian, H., & Bashir, M. (2003) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840300800205 · Cited by 58
Regulation of protein prenylation
Jung, D., & Bachmann, H. S. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114915 · Cited by 54
Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors
Rowan, C. G., Brinker, A. D., Nourjah, P. A., Chang, J. T., Mosholder, A. D., Barrett, J. S., & Avigan, M. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1711 · Cited by 56
Spray-Dried Amorphous Solid Dispersions of Atorvastatin Calcium for Improved Supersaturation and Oral Bioavailability
Kwon, J., Giri, B. R., Song, E. S., Bae, J., Lee, J., & Kim, D. W. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11090461 · Cited by 55
The role of statins in lung cancer
Amin, F., Fathi, F., Reiner, Ž., Banach, M., & Sahebkar, A. (2021) · Archives of Medical Science · doi:10.5114/aoms/123225 · Cited by 54
Systematic review and meta‐analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present
McClure, D. L., Valuck, R. J., Glanz, M., & Hokanson, J. E. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1341 · Cited by 52
Atorvastatin inhibits pancreatic carcinogenesis and increases survival in LSL‐KrasG12D‐LSL‐Trp53R172H‐Pdx1‐Cre mice
Liao, J., Chung, Y. T., Yang, A. L., Zhang, M., Li, H., Zhang, W., Yan, L. W., & Yang, G. (2012) · Molecular Carcinogenesis · doi:10.1002/mc.21916 · Cited by 52
Simultaneous quantification of atorvastatin and active metabolites in human plasma by liquid chromatography–tandem mass spectrometry using rosuvastatin as internal standard
Nirogi, R. V. S., Kandikere, V. N., Shukla, M., Mudigonda, K., Maurya, S., Boosi, R., & Anjaneyulu, Y. (2006) · Biomedical Chromatography · doi:10.1002/bmc.622 · Cited by 50
Early statin treatment prior to primary PCI for acute myocardial infarction: REPERATOR, a randomized placebo‐controlled pilot trial
Post, S., Post, M. C., den Branden, B. J. V., Eefting, F. D., Goumans, M., Stella, P. R., van Es, H. W., Wildbergh, T. X., Rensing, B. J. W. M., & Doevendans, P. A. (2012) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.23449 · Cited by 50
Effects of atorvastatin and simvastatin on atrial plateau currents
Vaquero, M., Caballero, R., Gómez, R. J., Núñez, L., Tamargo, J. L., & Delpón, E. (2007) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2007.03.807 · Cited by 49
Simultaneous quantitation of atorvastatin and its two active metabolites in human plasma by liquid chromatography/(–) electrospray tandem mass spectrometry
Partani, P., Verma, S. M., Gurule, S. J., Khuroo, A. H., & Monif, T. (2013) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2013.09.007 · Cited by 50
Decreasing LDL Cholesterol and Medication Cost With Every‐Other‐Day Statin Therapy
Juszczyk, M. A., Seip, R. L., & Thompson, P. D. (2005) · Preventive Cardiology · doi:10.1111/j.0197-3118.2005.04404.x · Cited by 47
Preparation of Candesartan and Atorvastatin Nanoparticles by Solvent Evaporation
Vaculíková, E., Grünwaldová, V., Král, V., Dohnal, J., & Jampílek, J. (2012) · Molecules · doi:10.3390/molecules171113221 · Cited by 47
Atorvastatin in the Treatment of Primary Hypercholesterolemia and Mixed Dyslipidemias
Yee, H. S., & Fong, N. T. (1998) · Annals of Pharmacotherapy · doi:10.1345/aph.17231 · Cited by 47
Mechanism of Drug-Drug Interactions Between Warfarin and Statins
Shaik, A. N., Bohnert, T., Williams, D. A., Gan, L. L., & LeDuc, B. W. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.03.011 · Cited by 45
Treatment with atorvastatin partially protects the rat heart from harmful catecholamine effects
Schmechel, A., Grimm, M. F., El‐Armouche, A., Hoppner, G., Schwoerer, A. P., Ehmke, H., & Thomas Eschenhagen, A. (2009) · Cardiovascular Research · doi:10.1093/cvr/cvp005 · Cited by 45
Development And Characterization Of Atorvastatin Calcium Loaded chitosan Nanoparticles For Sustain Drug Delivery
Bathool, A., Vishakante, G. D., Khan, M. S., & Shivakumar, H. G. (2012) · Advanced Materials Letters · doi:10.5185/amlett.2012.icnano.153 · Cited by 45
Atorvastatin Reduces Oxidative Stress in the Rostral Ventrolateral Medulla of Stroke-Prone Spontaneously Hypertensive Rats
Kishi, T., Hirooka, Y., Shimokawa, H., Takeshita, A., & Sunagawa, K. (2008) · Clinical and Experimental Hypertension · doi:10.1080/10641960701813429 · Cited by 43
HMG-CoA reductase inhibitors
Illingworth, D. R., & Tobert, J. A. (2001) · Advances in protein chemistry · doi:10.1016/s0065-3233(01)56003-9 · Cited by 43
Statins decrease TNF-α-induced osteoprotegerin production by endothelial cells and smooth muscle cells in vitro
Cohen, E. B.-T., Hohensinner, P. J., Kaun, C., Maurer, G., Huber, K., & Wojta, J. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.09.007 · Cited by 41
Atorvastatin prevents hypoxia-induced inhibition of endothelial nitric oxide synthase expression but does not affect heme oxygenase-1 in human microvascular endothelial cells
Łoboda, A., Jaźwa, A., Jozkowicz, A., Dorosz, J., Balla, J., Molema, G., & Dulak, J. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.03.015 · Cited by 41
P‐Glycoprotein Inhibition Exacerbates Paclitaxel Neurotoxicity in Neurons and Patients With Cancer
Stage, T. B., Mortensen, C., Khalaf, S., Steffensen, V., Hammer, H., Xiong, C., Nielsen, F., Poetz, O., Svenningsen, Å. F., Rodríguez‐Antona, C., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1847 · Cited by 40
Oral Nanoparticulate Atorvastatin Calcium is More Efficient and Safe in Comparison to Lipicure® in Treating Hyperlipidemia
Meena, A. K., Ratnam, D. V., Chandraiah, G., Ankola, D. D., Rao, P. R., & Kumar, M. N. V. R. (2008) · Lipids · doi:10.1007/s11745-007-3142-5 · Cited by 40
Preparation and Characterization of Oil in Water Nano-Reservoir Systems for Improved Oral Delivery of Atorvastatin
Mustafa, G., Khan, Z. I., Bansal, T., & Talegaonkar, S. (2009) · Current Nanoscience · doi:10.2174/157341309789377989 · Cited by 39
Statin-induced expression of CD59 on vascular endothelium in hypoxia: a potential mechanism for the anti-inflammatory actions of statins in rheumatoid arthritis
Kinderlerer, A. R., Steinberg, R., Johns, M. S., Harten, S. K., Lidington, E. A., Haskard, D. O., Maxwell, P. H., & Mason, J. C. (2006) · Arthritis Research & Therapy · doi:10.1186/ar2019 · Cited by 38
In vitro effects of atorvastatin on lipopolysaccharide-induced gene expression in endometriotic stromal cells
Sharma, I., Dhawan, V., Mahajan, N., Saha, S. C., & Dhaliwal, L. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2009.10.003 · Cited by 38
Pharmacotherapeutic Management of Gastrointestinal Bleeding in Patients with Continuous‐Flow Left Ventricular Assist Devices
Sieg, A. C., Moretz, J. D., Horn, E. T., & Jennings, D. L. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2016 · Cited by 35
Atorvastatin attenuates homocysteine-induced apoptosis in human umbilical vein endothelial cells via inhibiting NADPH oxidase-related oxidative stress-triggered p38MAPK signaling
Bao, X.-M., Wu, C., & Lü, G. (2009) · Acta Pharmacologica Sinica · doi:10.1038/aps.2009.135 · Cited by 35
Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the treatment of patients with hypercholesterolemia: a meta-analysis of clinical trials
Kong, S. X., Crawford, S. Y., Gandhi, S., Seeger, J. D., Schumock, G. T., Lam, N. P., Stubbings, J., & Schoen, M. D. (1997) · Clinical Therapeutics · doi:10.1016/s0149-2918(97)80102-6 · Cited by 34
Rosuvastatin Treatment Protects Against Nitrate-Induced Oxidative Stress
Otto, A., Fontaine, D. J., Fontaine, J., & Berkenboom, G. M. (2005) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000167010.98177.78 · Cited by 33
Cerivastatin and atorvastatin inhibit IL-3-dependent differentiation and IgE-mediated histamine release in human basophils and downmodulate expression of the basophil-activation antigen CD203c/E-NPP3
Majlesi, Y., Samorapoompichit, P., Hauswirth, A. W., Schernthaner, G.-H., Ghannadan, M., Baghestanian, M., Rezaie-Majd, A., Valenta, R., Sperr, W. R., Bühring, H., et al. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0202075 · Cited by 33
Combination of Phospholipid Complex and Submicron Emulsion Techniques for Improving Oral Bioavailability and Therapeutic Efficacy of Water-Insoluble Drug
Qin, L., Niu, Y., Wang, Y., & Chen, X. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b01061 · Cited by 31
Optimization of transdermal atorvastatin calcium – Loaded proniosomes: Restoring lipid profile and alleviating hepatotoxicity in poloxamer 407-induced hyperlipidemia
Eltellawy, Y. A., El-Kayal, M., Abdel-Rahman, R. F., Salah, S., & Shaker, D. S. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.120163 · Cited by 31
ANTI‐OXIDANT EFFECTS OF ATORVASTATIN IN DEXAMETHASONE‐INDUCED HYPERTENSION IN THE RAT
Mondo, C. K., Yang, W., Zhang, N., & Huang, T. (2006) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2006.04482.x · Cited by 31
Treatment of experimental autoimmune uveoretinitis with atorvastatin and lovastatin
Kohno, H., Sakai, T., Saitô, S., Okano, K., & Kitahara, K. (2007) · Experimental Eye Research · doi:10.1016/j.exer.2006.11.011 · Cited by 31
An atorvastatin calcium and poly(L-lactide-co-caprolactone) core-shell nanofiber-covered stent to treat aneurysms and promote reendothelialization
Chu, J., Chen, L., Mo, Z., Bowlin, G. L., Minden‐Birkenmaier, B. A., Morsi, Y., Aldalbahi, A. K., El-Newehy, M. H., Wang, W., & Mo, X. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.04.044 · Cited by 30
Atorvastatin calcium encapsulated eudragit nanoparticles with enhanced oral bioavailability, safety and efficacy profile
Kumar, N., Chaurasia, S., Patel, R. R., Khan, G., Kumar, V., & Mishra, B. (2015) · Pharmaceutical Development and Technology · doi:10.3109/10837450.2015.1108983 · Cited by 29
Combination Therapy with Atorvastatin and Amlodipine Suppresses Angiotensin II-Induced Aortic Aneurysm Formation
Takahashi, K., Matsumoto, Y., Do.e, Z., Kanazawa, M., Satoh, K., Shimizu, T., Sato, A., Fukumoto, Y., & Shimokawa, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072558 · Cited by 28
PD-PK evaluation of freeze-dried atorvastatin calcium-loaded poly-ε-caprolactone nanoparticles
Ahmed, I. S., Hosary, R. E., Shalaby, S. H., Abd‐Rabo, M. M., ElKhateeb, D. G., & Nour, S. A. E.-K. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.03.045 · Cited by 28
Statins in Low Doses Reduce VEGF and bFGF Serum Levels in Patients with Type 2 Diabetes Mellitus
Dworacka, M., Krzyżagórska, E., Wesołowska, A., Borowska, M., Iskakova, S., & Dworacki, G. (2014) · Pharmacology · doi:10.1159/000357476 · Cited by 27
Inhibitory effect of dietary atorvastatin and celecoxib together with voluntary running wheel exercise on the progression of androgen-dependent LNCaP prostate tumors to androgen independence
Zheng, X., CUI, X.-X., Gao, Z., Zhao, Y., SHI, Y., Huang, M., Liu, Y., Wagner, G. C., Lin, Y., Shih, W. J., et al. (2011) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2011.203 · Cited by 26
Construction of Atorvastatin Dose–Response Relationships Using Data from a Large Population‐Based DNA Biobank
Peissig, P. L., Sirohi, E., Berg, R. L., Brown‐Switzer, C., Ghebranious, N., McCarty, C. A., & Wilke, R. A. (2007) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2006.00035.x · Cited by 26
Could Statins Be Useful in the Treatment of Patients With Migraine?
Liberopoulos, E. N., & Mikhailidis, D. P. (2006) · Headache The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2006.00293.x · Cited by 25
Atorvastatin inhibits angiotensin-converting enzyme induction in differentiating human macrophages
Saijonmaa, O. J., Nyman, T., & Fyhrquist, F. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00920.2006 · Cited by 24
No Pharmacokinetic or Pharmacodynamic Interaction Between Atorvastatin and the Oral Direct Thrombin Inhibitor Ximelagatran
Sarich, T. C., Schützer, K.-M., Dorani, H., Wall, U., KALIES, I., Ohlsson, L., & Eriksson, U. G. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004268047 · Cited by 24
Alternate-day Dosing with Statins
Marcus, G. M., Baumgarten, A. J., Fritz, W. L., & Nolan, P. E. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.08.007 · Cited by 23
Development and validation of a RP-HPLC method for assay of Atorvastatin and its application in dissolution studies on thermosensitive hydrogel-based nanocrystals
Kurakula, M., Sobahi, T. R., El-Helw, A.-R., & Abdelaal, M. Y. (2014) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v13i10.16 · Cited by 23

Authors: Cilla, D. D., Whitfield, L. R., Gibson, D. M., Sedman, A. J., & Posvar, E. L.
Corresponding author: Sedman, Allen J.
Venue: Clinical Pharmacology & Therapeutics
Publisher: Wiley
Published: 1996-12
Volume: 60
Issue: 6
Pages: 687-695
ISSN: 0009-9236 (ISSN-L)
1532-6535
DOI: 10.1016/s0009-9236(96)90218-0
OpenAlex: W1971242943
Cited by: 204
References: 8
Citations by year: 2026: 1 · 2025: 5 · 2024: 5 · 2023: 9 · 2022: 2 · 2021: 7 · 2020: 5 · 2019: 7 · 2018: 4 · 2017: 4 · 2016: 6 · 2015: 8 · 2014: 11 · 2013: 4 · 2012: 9
FWCI: 4.99
Type: journal article
Language: en
Open access: closed
Locations: Clinical Pharmacology & Therapeutics (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords: atorvastatin, statins, multiple-dose pharmacokinetics, pharmacodynamics, dose proportionality, LDL cholesterol lowering, total cholesterol, elimination half-life, drug accumulation, adverse events, drug safety, healthy volunteers
MeSH terms: Atorvastatin, Acyl Coenzyme A, Adult, Anticholesteremic Agents, Cholesterol, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Enzyme Inhibitors, Female, Half-Life, Heptanoic Acids, Humans, Male, Middle Aged, Pyrroles, Reference Values, Linear Models, Least-Squares Analysis, Area Under Curve

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks